{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:41:30Z","timestamp":1791272490225,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":2761,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1093\/annonc\/mdr356","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T07:27:32Z","timestamp":1315553252000},"page":"1151-1156","source":"Crossref","is-referenced-by-count":42,"title":["High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy"],"prefix":"10.1016","volume":"23","author":[{"given":"B.","family":"Bouvard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hopp\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Souli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Georgin-Mege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jadaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Petit Le Manac\u2019h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laffitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Levasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Audran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chappard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr356_bb0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdr356_bb0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdr356_bb0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr356_bb0025","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr356_bb0030","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr356_bb0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.maturitas.2009.05.008","article-title":"Aromatase inhibitors in breast cancer","volume":"63","author":"Hiscox","year":"2009","journal-title":"Maturitas"},{"key":"10.1093\/annonc\/mdr356_bb0040","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr356_bb0045","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr356_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdr356_bb0055","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr356_bb0060","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdr356_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cca.2005.10.010","article-title":"Practical considerations in PTH testing","volume":"366","author":"Souberbielle","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1093\/annonc\/mdr356_bb0070","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jacc.2008.08.050","article-title":"Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?","volume":"52","author":"Lee","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/annonc\/mdr356_bb0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","article-title":"Hyperparathyroidism","volume":"374","author":"Fraser","year":"2009","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr356_bb0080","first-page":"155","article-title":"Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue","volume":"29","author":"McCarthy","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdr356_bb0085","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ajcn\/85.6.1586","article-title":"Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial","volume":"85","author":"Lappe","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1093\/annonc\/mdr356_bb0090","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/jnci\/djn360","article-title":"Calcium plus vitamin D supplementation and the risk of breast cancer","volume":"100","author":"Chlebowski","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr356_bb0095","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1200\/JCO.2008.20.0725","article-title":"Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer","volume":"27","author":"Goodwin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr356_bb0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdr356_bb0105","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","article-title":"Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study","volume":"42","author":"Geisler","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdr356_bb0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00223-010-9454-0","article-title":"Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study","volume":"88","author":"Rejnmark","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"10.1093\/annonc\/mdr356_bb0115","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdr356_bb0120","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdr356_bb0125","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr356_bb0130","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/cncr.21335","article-title":"Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer","volume":"104","author":"Chen","year":"2005","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdr356_bb0135","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00198-004-1702-6","article-title":"Epidemiology of osteoporotic fractures","volume":"16","author":"Johnell","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdr356_bb0140","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2010.07.007","article-title":"Which fractures are most attributable to osteoporosis?","volume":"64","author":"Warriner","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1093\/annonc\/mdr356_bb0145","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/jbmr.5650110719","article-title":"The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study","volume":"11","author":"O\u2019Neill","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdr356_bb0150","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1359\/jbmr.2000.15.7.1384","article-title":"Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures","volume":"15","author":"Oleksik","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdr356_bb0155","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","article-title":"Population-based study of survival after osteoporotic fractures","volume":"137","author":"Cooper","year":"1993","journal-title":"Am J Epidemiol"},{"key":"10.1093\/annonc\/mdr356_bb0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdr356_bb0165","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors: results from the Women\u2019s Health Initiative Observational Study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1093\/annonc\/mdr356_bb0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3816\/CBC.2006.n.021","article-title":"Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors","volume":"7","author":"Mincey","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdr356_bb0175","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdr356_bb0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2009.05378.x","article-title":"Looking beyond bone mineral density: imaging assessment of bone quality","volume":"1192","author":"Griffith","year":"2010","journal-title":"Ann N Y Acad Sci"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/5\/1151\/476091\/mdr356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T05:10:45Z","timestamp":1624425045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419346708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0923753419346708"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr356","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}